Search for other papers by Yanling Cai in
Google Scholar
PubMed
Search for other papers by Yan Yang in
Google Scholar
PubMed
Search for other papers by Xiao Pang in
Google Scholar
PubMed
Search for other papers by Suping Li in
Google Scholar
PubMed
Introduction Thyroid cancer (TC) is the most common endocrine tumor, and its global incidence is increasing annually; however, the global incidence among females is 10.1 per 100,000, which is three times higher than the incidence among males
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Kim Magaly Pabst in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
Search for other papers by Robert Seifert in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Nader Hirmas in
Google Scholar
PubMed
Search for other papers by Martina Broecker-Preuss in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Manuel Weber in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Wolfgang Peter Fendler in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Timo Bartel in
Google Scholar
PubMed
Institute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
Search for other papers by Sarah Theurer in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Ken Herrmann in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Rainer Görges in
Google Scholar
PubMed
over a period of >10 years. Conclusion U-hsTg measurement in patients with differentiated thyroid cancer within 24 months after completing radioiodine therapy showed higher predictive power than s-Tg measurement for RFS for a time period >10
Search for other papers by Mahmoud Al-Masri in
Google Scholar
PubMed
Search for other papers by Tawfiq Al-Shobaki in
Google Scholar
PubMed
Search for other papers by Hani Al-Najjar in
Google Scholar
PubMed
Search for other papers by Rafal Iskanderian in
Google Scholar
PubMed
Search for other papers by Enas Younis in
Google Scholar
PubMed
Search for other papers by Niveen Abdallah in
Google Scholar
PubMed
Search for other papers by Abdelghani Tbakhi in
Google Scholar
PubMed
Search for other papers by Hussam Haddad in
Google Scholar
PubMed
Search for other papers by Mohammad Al-Masri in
Google Scholar
PubMed
Search for other papers by Zeinab Obeid in
Google Scholar
PubMed
Search for other papers by Awad Jarrar in
Google Scholar
PubMed
Introduction Papillary thyroid carcinoma (PTC) is the most prevalent subtype of thyroid cancer accounting for approximately 85–88% of cases. The incidence of PTC is rapidly increasing, in contrast to other subtypes ( 1 ). The increase in the
Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Thomas Crezee in
Google Scholar
PubMed
Search for other papers by Mirela Petrulea in
Google Scholar
PubMed
Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Doina Piciu in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Tumors, Institute of Oncology ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania
Search for other papers by Martin Jaeger in
Google Scholar
PubMed
Search for other papers by Jan W A Smit in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Tumors, Institute of Oncology ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania
Search for other papers by Theo S Plantinga in
Google Scholar
PubMed
Endocrinology Clinic, Cluj County Emergency Hospital, Cluj-Napoca, Romania
Search for other papers by Carmen E Georgescu in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Tumors, Institute of Oncology ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania
Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed
Background In recent years, the incidence of non-medullary thyroid cancer (NMTC) has steadily increased ( 1 , 2 , 3 , 4 ). Although most NMTC patients have a favorable prognosis, 20–30% of patients with locally advanced or metastatic
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Jes Sloth Mathiesen in
Google Scholar
PubMed
Search for other papers by Jens Peter Kroustrup in
Google Scholar
PubMed
Search for other papers by Peter Vestergaard in
Google Scholar
PubMed
Center for Rare Diseases, Aarhus University Hospital, Aarhus N, Denmark
Search for other papers by Kirstine Stochholm in
Google Scholar
PubMed
Search for other papers by Per Løgstrup Poulsen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Sten Schytte in
Google Scholar
PubMed
Search for other papers by Stefano Christian Londero in
Google Scholar
PubMed
Search for other papers by Henrik Baymler Pedersen in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
Search for other papers by Bjarki Ditlev Djurhuus in
Google Scholar
PubMed
Search for other papers by Jens Bentzen in
Google Scholar
PubMed
Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark
Search for other papers by Sören Möller in
Google Scholar
PubMed
Search for other papers by Mette Gaustadnes in
Google Scholar
PubMed
Search for other papers by Maria Rossing in
Google Scholar
PubMed
Search for other papers by Finn Cilius Nielsen in
Google Scholar
PubMed
Search for other papers by Kim Brixen in
Google Scholar
PubMed
Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
Search for other papers by Anja Lisbeth Frederiksen in
Google Scholar
PubMed
Search for other papers by Christian Godballe in
Google Scholar
PubMed
Search for other papers by the Danish Thyroid Cancer Group (DATHYRCA) in
Google Scholar
PubMed
/17801). Methods The MTC cohort was based on the Danish Cancer Registry, the Danish Pathology Register and the Danish Thyroid Cancer Database, which have prospectively collected data since 1943, 1968 and 1996, respectively. The first year, in which registration
Search for other papers by Hanrong Zhang in
Google Scholar
PubMed
Search for other papers by Junxin Chen in
Google Scholar
PubMed
Search for other papers by Xin Chen in
Google Scholar
PubMed
Search for other papers by Chuimian Zeng in
Google Scholar
PubMed
Search for other papers by Pengyuan Zhang in
Google Scholar
PubMed
Search for other papers by Jiewen Jin in
Google Scholar
PubMed
Search for other papers by Haipeng Xiao in
Google Scholar
PubMed
Search for other papers by Yanbing Li in
Google Scholar
PubMed
Search for other papers by Hongyu Guan in
Google Scholar
PubMed
Search for other papers by Hai Li in
Google Scholar
PubMed
Background: Transforming growth factor beta receptor III (TGFBR3) has been shown to play a tumor suppressive role in a variety of cancers. However, its role in papillary thyroid cancer (PTC) remains unknown.
Method: TGFBR3 expression levels in PTC were analyzed utilizing TCGA and GEO database. Edu, wounding healing and Transwell assays were used to evaluate cell proliferation, migration and invasion. Transcriptome sequencing, qRT-PCR and Western blotting were used to detect the underlying mechanism of TGFBR3 in PTC progression.
Result: This study demonstrated that TGFBR3 expression was significantly down-regulated in PTC compared to normal thyroid tissues. Low expression of TGFBR3 was associated with poor prognosis of patients with PTC. Furthermore, TGFBR3 expression positively correlated with thyroid differentiation score. In investigating the biological impact of TGFBR3 over-expression in PTC cell lines, we found that the proliferation, migration and invasion of PTC cells were significantly inhibited in response to TGFBR3 overexpression. Moreover, we also demonstrated that overexpression of TGFBR3 inhibited PI3K/AKT pathway and epithelial mesenchymal transformation processes. Lastly, TGFBR3 expression was found to be involved in tumor immune infiltration, highlighting its potential influence on immune dynamics within the tumor microenvironment in PTC.
Conclusion: TGFBR3 plays a tumor suppressive role in PTC progression by inhibiting PI3K/AKT pathway and EMT.
Search for other papers by Weiwei Liang in
Google Scholar
PubMed
Search for other papers by Junxin Chen in
Google Scholar
PubMed
Search for other papers by Hai Li in
Google Scholar
PubMed
Search for other papers by Pengyuan Zhang in
Google Scholar
PubMed
Search for other papers by Hongyu Guan in
Google Scholar
PubMed
Search for other papers by Yanbing Li in
Google Scholar
PubMed
Background: Collagen type VIII α 1 chain (COL8A1), a collagen type VIII protein, has been suggested to exert various functions in progression of multiple cancers. However, the effect of COL8A1 in papillary thyroid cancer (PTC) has not been elucidated.
Methods: The Cancer Genome Atlas (TCGA) databases were applied to investigate the COL8A1 expression and its clinical significance in PTC. The COL8A1 expression level was further validated using Gene Expression Omnibus (GEO) data and clinical paired PTC tissues. Additionally, Kaplan-Meier curve was used to analyze the prognosis. The cell migrative and invasive abilities were evaluated by wound healing assay and Transwell assay. CCK8 assays were used to evaluate proliferation of PTC cells. Western blotting was conducted to explore the potential mechanisms involved in the pro-tumor role of COL8A1. The correlation between immune cell infiltration and COL8A1 was analyzed using Tumor Immune Estimation Resource (TIMER) database and the single-sample GSEA (ssGSEA) method.
Results: We found that COL8A1 was upregulated in PTC (P<0.05). High COL8A1 expression level was significantly associated with advanced T stage (P<0.01), N stage (P<0.001) and poor prognosis (P=0.0142) in PTC. Furthermore, cell migration and invasion were significantly reduced following COL8A1 knockdown (P<0.001). Mechanistic studies demonstrated that the epithelial-to-mesenchymal transition (EMT) related proteins (FN1, MMP9, MMP7, ZEB2 and Twist1) and phosphorylation of AKT and ERK were obviously down-regulated after COL8A1 knockdown (P<0.01). Moreover, COL8A1 expression was correlated with immune cell infiltration.
Conclusion: Our study demonstrates that COL8A1 may function as an oncogene and a potential prognostic biomarker for PTC patients.
Search for other papers by Norra Kwong in
Google Scholar
PubMed
Search for other papers by Ellen Marqusee in
Google Scholar
PubMed
Division of Endocrinology, Endocrine Division, Hypertension and Diabetes, Thyroid Section, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue Boston, Massachusetts 02115, USA
Search for other papers by Michael S Gordon in
Google Scholar
PubMed
Search for other papers by P Reed Larsen in
Google Scholar
PubMed
Division of Endocrinology, Endocrine Division, Hypertension and Diabetes, Thyroid Section, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue Boston, Massachusetts 02115, USA
Search for other papers by Jeffrey R Garber in
Google Scholar
PubMed
Search for other papers by Matthew I Kim in
Google Scholar
PubMed
Search for other papers by Erik K Alexander in
Google Scholar
PubMed
Introduction Well-differentiated thyroid cancer is common, easily identified, and often curable. While the incidence of thyroid cancer has nearly tripled in the past three decades, mortality rates have remained stable (1, 2, 3) . This underscores
Search for other papers by Teresa Kraus in
Google Scholar
PubMed
Search for other papers by Natalia Shengelia-de Lange in
Google Scholar
PubMed
Search for other papers by Holger Einspieler in
Google Scholar
PubMed
Search for other papers by Marcus Hacker in
Google Scholar
PubMed
Search for other papers by Alexander Haug in
Google Scholar
PubMed
Search for other papers by Elisabeth Kretschmer-Chott in
Google Scholar
PubMed
Search for other papers by Georgios Karanikas in
Google Scholar
PubMed
this article). There was no statistically significant difference between the TNM staging in patients from Vienna and Tbilisi. The distribution of histotype showed 345 patients with papillary thyroid cancer (PTC) (93%) and 25 patients with follicular
Search for other papers by Rui M B Maciel in
Google Scholar
PubMed
Search for other papers by Cleber P Camacho in
Google Scholar
PubMed
Search for other papers by Lígia V M Assumpção in
Google Scholar
PubMed
Search for other papers by Natassia E Bufalo in
Google Scholar
PubMed
Search for other papers by André L Carvalho in
Google Scholar
PubMed
Search for other papers by Gisah A de Carvalho in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Luciana A Castroneves in
Google Scholar
PubMed
Search for other papers by Francisco M de Castro Jr in
Google Scholar
PubMed
Search for other papers by Lucieli Ceolin in
Google Scholar
PubMed
Search for other papers by Janete M Cerutti in
Google Scholar
PubMed
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Search for other papers by Tânia M B L Ferraz in
Google Scholar
PubMed
Search for other papers by Carla V Ferreira in
Google Scholar
PubMed
Hospital Santa Rita de Cássia, Vitória, Espírito Santo, Brazil
Search for other papers by M Inez C França in
Google Scholar
PubMed
Search for other papers by Henrique C R Galvão in
Google Scholar
PubMed
Search for other papers by Fausto Germano-Neto in
Google Scholar
PubMed
Search for other papers by Hans Graf in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Ilda S Kunii in
Google Scholar
PubMed
Search for other papers by Márcio W Lauria in
Google Scholar
PubMed
Search for other papers by Vera L G Leal in
Google Scholar
PubMed
Search for other papers by Susan C Lindsey in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Delmar M Lourenço Jr in
Google Scholar
PubMed
Search for other papers by Léa M Z Maciel in
Google Scholar
PubMed
Search for other papers by Patrícia K R Magalhães in
Google Scholar
PubMed
Search for other papers by João R M Martins in
Google Scholar
PubMed
Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil
Universidade de Fortaleza, Fortaleza, Ceará, Brazil
Search for other papers by M Cecília Martins-Costa in
Google Scholar
PubMed
Search for other papers by Gláucia M F S Mazeto in
Google Scholar
PubMed
Search for other papers by Anelise I Impellizzeri in
Google Scholar
PubMed
Search for other papers by Célia R Nogueira in
Google Scholar
PubMed
Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata, Barretos, São Paulo, Brazil
Search for other papers by Edenir I Palmero in
Google Scholar
PubMed
Search for other papers by Cencita H C N Pessoa in
Google Scholar
PubMed
Search for other papers by Bibiana Prada in
Google Scholar
PubMed
Search for other papers by Débora R Siqueira in
Google Scholar
PubMed
Escola Fiocruz de Governo, Fundação Oswaldo Cruz and Ministério da Saúde, Brasília, Distrito Federal, Brazil
Search for other papers by Maria Sharmila A Sousa in
Google Scholar
PubMed
Vall d’Hebron Institute of Oncology (VHIO), CIBERONC, Barcelona, Spain
Search for other papers by Rodrigo A Toledo in
Google Scholar
PubMed
Search for other papers by Flávia O F Valente in
Google Scholar
PubMed
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Search for other papers by Laura S Ward in
Google Scholar
PubMed
Search for other papers by Shana S Weber in
Google Scholar
PubMed
Search for other papers by Rita V Weiss in
Google Scholar
PubMed
Search for other papers by Ji H Yang in
Google Scholar
PubMed
Search for other papers by Magnus R Dias-da-Silva in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Ana O Hoff in
Google Scholar
PubMed
Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Sergio P A Toledo in
Google Scholar
PubMed
Search for other papers by Ana L Maia in
Google Scholar
PubMed
Brazilian centers involved in the diagnosis and treatment of thyroid cancer. Declaration of interest The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported